EvkeezaActive Ingredient(s): Evinacumab-dgnb
FDA Approved: * February 11, 2021
Pharm Company: * REGENERON PHARMACEUTICALS
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH). Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials. Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.